Abstract:BACKGROUND & OBJECTIVE:Vinorelbine (NVB), paclitaxel (TAX), and gemcitabine (GEM) are first-line chemotherapeutic drugs in the treatment for non-small cell lung cancer (NSCLC) currently. There are many domestically retrospective studies to compare efficacies and adverse reactions among these three regimens, all of which has composed of cisplatin (DDP). This randomized study was to investigate the efficacies and toxicities of these three regimens in NSCLC treatment, in order to choose a feasible regimen for NSCLC patients.METHODS:A total of 276 NSCLC patients were randomly assigned to a regimen of NP (NVB plus DDP ), or TP (TAX plus DDP), or GP (GEM plus DDP). Efficacies and toxicities were analyzed and compared after two cycles.RESULTS:The response rates were 42.3% (41/97) in NP arm, 43.0% (40/93) in TP arm, and 43.4% (36/83) in GP arm, and complete remission rates were 1.0% (1/97), 2.2% (1/93) and (0/83) respectively, without significant difference. The median survival time, disease-free survival time and 1-year survival rate were 8.5 months, 4.1 months and 31.9%; 8.8 months, 3.8 months and 33.3%, and 9.2 months, 3.9 months, 31.3%, respectively in NP, TP and GP arms without significant difference. The major adverse reactions were stage 3 to 4 myelo-suppression, nausea/vomiting, fatigue and phlebitis. There were highest incidences of leucopenia (42.2%), neutropenia (36.2%) and lowest incidence of thrombocytopenia (53.0%) in GP arm compared to NP arm (77.8%, 67.7%, 12.1%) or TP arm (71.0%, 57.0%, 13.0%) statistically (P<0.01 for all). The rates of nausea/vomiting in GP arm (16.8%) and TP arm (25.8%) were significantly lower than in NP arm (41.4%)(P<0.05); and the rate of fatigue in GP arm (38.5%) or phlebitis in NP arm was most frequent among the three arms (P=0.000, 0.008 respectively).CONCLUSIONS:There is no significant difference in short-term efficacy of chemotherapy regimen NP, TP and GP. TP and GP regimens, both of which possesses its own advantage, are more tolerable than NP regimen which has the most side effects.

Comparison of Short-term Efficacy between the NP and GP Regimens in the Treatment of Advanced Non-small-cell Lung Canaer

A Clinical Study on Efficacy and Toxicity of NP in Contrast to the MNP Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

A Comparative Study for Vinorelbine with Cisplatin Plus Mitomycin and Vinorelbine with Cisplatin in Advanced Non-Small-cell Lung Cancer

Clinical Evaluation of NP and GP in Treatment of Patiens with Non-Small Cell Lung Cancer

Chemotherapy Based on Regimes of Gemcitabine Plus Cisplatin or Vinorelbine Plus Cisplatin in Patients with Advanced NSCLC

The application of different chemotherapy regimens in non-small cell lung cancer

Comparasion on Two Combination Regimens of Nedaplatin Plus Gemcitabine and Cisplatin Plus Gemcitabine for Treatment of Patients with Advanced Non Small-cell Lung Cancer

Three Cisplatin-Based Regimens in Treatment of Advanced Non-Small Cell Lung Cancer

[A Randomized Comparative Trial of Three Combined Regimens Containing Cisplatin for Treatment of Advanced Non-Small Cell Lung Cancer].

Compare and Evaluate Two Combination Regimens of Vinorelbine Plus Gemcitabine and Cisplatin Pins Vinorelbine for Treatment of Patients with Advanced Non-Small-cell Lung Cancer

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

[Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].

[A randomized clinical trial of gemcitabine plus cisplatin compared with gemcitabine plus vinorelbine in the treatment of non-small cell lung cancer].

[Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].

[Comparison of Cisplatin Combined with Gemcitabine Versus Cisplatin Combined with Vinorelbine Regimen for Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Clinical Study of Original Chemotherapy for Advanced Non-Small Cell Lung Cancer with GP Regimen

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Vinorelbine in the Treatment of Advanced Non-Small Cell Lung Cancer (Nsclc).

Clinical Study on Gemcitabine Combined with Nedaplatin or Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

Clinical Study of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Treatment of Patients with Advanced Non-Small-cell Lung Cancer